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Introduction
Natural killer T (NKT) cells are a specialized T-cell lineage
with unique functional characteristics that distinguish them
from conventional T lymphocytes.1 Their role in immune
responses that require opposite regulatory pathways has
been attributed to an apparent flexibility of NKT cells with
regard to their predominant cytokine profile.2 Peripheral
NKT cells display a memory-activated phenotype and can
rapidly secrete large amounts of cytokines including inter-
feron-c (IFN-c), tumour necrosis factor-a (TNF-a), inter-
leukin-4 (IL-4) and IL-13 upon antigenic stimulation.3
The NKT cells are a heterogeneous population of lym-
phocytes4 that has attracted a great deal of attention
because of their potential to link the innate and adaptive
arms of the immune system. Characteristically, they
respond very rapidly to certain stimuli, rendering them
able to activate a number of immune effectors.5 Presenta-
tion of a-galactosylceramide (a-GalCer) by CD1d-express-
ing antigen-presenting cells, such as dendritic cells and B
cells, results in rapid activation of NKT cells. It is clear
that the capacity to participate in early immune responses
and to modulate both innate and adaptive immunity con-
fers upon NKT cells the potential to mediate important
activities in the control of pathogens and subsequent
clearance of infections.6
Gansert et al.7 provided evidence that a-GalCer could
activate antimicrobial pathways in a CD1d-restricted
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Summary
Natural killer T (NKT) cells are a heterogeneous population of lympho-
cytes that recognize antigens presented by CD1d and have attracted atten-
tion because of their potential role linking innate and adaptive immune
responses. Peripheral NKT cells display a memory-activated phenotype
and can rapidly secrete large amounts of pro-inflammatory cytokines
upon antigenic activation. In this study, we evaluated NKT cells in the
context of patients co-infected with HIV-1 and Mycobacterium leprae. The
volunteers were enrolled into four groups: 22 healthy controls, 23 HIV-1-
infected patients, 20 patients with leprosy and 17 patients with leprosy
and HIV-1-infection. Flow cytometry and ELISPOT assays were per-
formed on peripheral blood mononuclear cells. We demonstrated that
patients co-infected with HIV-1 and M. leprae have significantly lower
NKT cell frequencies [median 0.022%, interquartile range (IQR): 0.007–
0.051] in the peripheral blood when compared with healthy subjects
(median 0.077%, IQR: 0.032–0.405, P < 0.01) or HIV-1 mono-infected
patients (median 0.072%, IQR: 0.030–0.160, P < 0.05). Also, more NKT
cells from co-infected patients secreted interferon-c after stimulation with
DimerX, when compared with leprosy mono-infected patients (P = 0.05).
These results suggest that NKT cells are decreased in frequency in HIV-1
and M. leprae co-infected patients compared with HIV-1 mono-infected
patients alone, but are at a more activated state. Innate immunity in
human subjects is strongly influenced by their spectrum of chronic infec-
tions, and in HIV-1-infected subjects, a concurrent mycobacterial infec-
tion probably hyper-activates and lowers circulating NKT cell numbers.
Keywords: co-infection; HIV-1; interferon-c; leprosy; Mycobacterium le-
prae; natural killer T cell
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manner in humans. The protection conferred by NKT
cells could be a result of the fact that the cytokines they
produce are not only critical in activating early innate
immune responses, but also favour the development of
classical pathogen-specific T-cell responses that are ulti-
mately responsible for clearing the infection.8
Leprosy is a debilitating chronic, infectious disease
caused by Mycobacterium leprae that involves mostly the
skin and peripheral nerves.9 The majority of infected indi-
viduals do not develop clinical leprosy, but a few subjects
manifest the disease depending on their immunological
status.10 A concern has been that with the increasing
prevalence of HIV-1 infection in many countries where
leprosy is endemic11 HIV-1 co-infection might shift the
clinical spectrum of leprosy from paucibacillary to multi-
bacillary forms, enhancing the transmission of
M. leprae.12 Frommel et al.13 revisited the overall rise in
HIV-1 seropositivity and the increase of such co-infec-
tions. An HIV-1-positive subject infected with M. leprae
might be expected to manifest the lepromatous form of
the disease or, alternatively, to develop rapid progression
from tuberculoid to lepromatous forms, as HIV-1 infec-
tion impairs the cellular immune response.14 In this
study, the frequency and ex vivo functions of NKT cells
in healthy controls, HIV-1-positive patients and HIV-1
and M. leprae co-infected patients were measured, and it
was shown that co-infected subjects have reduced NKT
cells in the peripheral blood when compared with healthy
subjects and leprosy mono-infected patients, but they
secrete more IFN-c when compared with leprosy mono-
infected patients.
Materials and methods
Subjects and sample collection
Volunteers were recruited at the Federal University of Sao
Paulo and the Federal University of Para´, Brazil. Written
informed consent was obtained from all volunteers accord-
ing to the guidelines of the Brazilian Ministry of Health,
and approved by the Institutional Review Board. Leprosy
patients were treated according to World Health Organi-
zation guidelines15 and the co-infected patients were trea-
ted with the appropriate multidrug therapy for
paucibacillary and multibacillary leprosy, when indicated.
The initial treatment for patients with HIV-1 infection or
HIV-1 and leprosy co-infection was defined using modi-
fied criteria adopted by the Brazilian Ministry of Health,
which includes patients with a CD4+ T-cell count < 350
cells/ll or clinical conditions related to AIDS.16 Leprosy
patients were matched for paucibacillary and multibacil-
lary forms to the cases in the co-infected group according
to World Health Organization criteria. The HIV-1 mono-
infected and co-infected patients received highly active
antiretroviral therapy and multidrug therapy. Patients
with immune reconstitution inflammatory syndrome were
not included in the study.17
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated
from volunteers and were stored in liquid nitrogen until
used in the assays. The following monoclonal antibodies
were used in the FACS assays: anti-HLA-DR-peridinin
chlorophyll protein (PerCP) (clone L243), from BD Bio-
sciences (San Jose, CA); CD4-phycoerythrin–cyanine-7
(PE-Cy7) (clone SK3), CD3-allophycocyanin–cyanine-7
(APC-Cy7) (clone SK7) and CD161 allophycocyanin
(APC) (clone DX12), from BD PharMingen (San Jose,
CA); and Va24-PE (clone C15), Vb11- FITC (clone C21)
from Immunotech (Marseille, France). All the antibodies
were used for cell-surface staining. Fluorescence minus
one was used for gating strategy.
After thawing, cells were centrifuged at 300 g for 5 min
and transferred into 96-well V-bottomed plates (Nunc,
Roskilde, Denmark) in 100 ll staining buffer [PBS sup-
plemented with 0.1% sodium azide (Sigma, St Louis,
MO) and 1% fetal bovine serum, pH 7.4–7.6] with the
surface monoclonal antibodies panel. Cells were incubated
at 4 in darkness for 30 min, washed twice, and re-sus-
pended in 100 ll fixation buffer [1% paraformaldehyde
(Polysciences, Warrington, PA) in PBS, (pH 7.4–7.6)].
Samples were acquired on a FACSCanto, using FACS-
DIVA software (BD Biosciences), and then analysed with
FLOWJO software version 9.2 (Tree Star, San Carlo, CA).
Fluorescence voltages were determined using matched
unstained cells. Compensation was carried out with
CompBeads (BD Biosciences) single-stained with CD3-
PerCP, CD4-FITC, CD8-APC-Cy7, CD4-PE-Cy7, CD3-PE
and CD3-APC. Samples were acquired until at least
800 000 events in a lymphocyte gate.
Antigen-loaded DimerX with a-GalCer
For DX-a-GalCer stimulation, 20 lg human CD1d-
immunoglobulin recombinant fusion proteins (DimerX;
BD Biosciences) was mixed with 5 lg a-GalCer (AXX-
ORA, San Diego, CA) in a final volume of 100 ll and
incubated overnight at 37. An additional 320 ll PBS was
added the next day. The antigen-loaded DimerX com-
plexes were added to culture wells at a final concentration
of 15 ll/ml. PBS was used as a loading (vehicle) control
for all a-GalCer stimulation assays. Titration of the
DimerX reagent was performed to ensure maximum
stimulation of all NKT cells in PBMC cultures.
Measurement of cytokine-producing cells by ELISPOT
To determine the amount of IFN-c-secreting and IL-4-
secreting cells, MAIP ELISPOT plates (Millipore, Billerica,
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MA) were coated with either anti-IFN-c (10 lg/ml) or
anti-IL-4 (15 lg/ml) (Mabtech, Nacka Strand, Sweden),
in PBS, 50 ll per well, each overnight at room temper-
ature. After three washes with PBS, PBMC (3 · 105)
were added, and incubated with or without DimerX-a-
GalCer stimulation (specific for NKT cells) or PMA
(50 ng/ml) plus ionomycin (500 ng/ml) as a positive
control; for negative control DimerX loaded with PBS
was used to establish the background level for each
group of patients. The plates were incubated at 37 in 5%
CO2 for 16–20 hr. At the end of the culture period, the
plates were washed twice with PBS and twice with PBS plus
0.1% Tween-20 (PBST), and the biotinylated antibodies
were added to the appropriate wells: anti-IL-4 (1 lg/ml)
(Mabtech) and anti-IFN-c (1 lg/ml) (Mabtech), in PBS
supplemented with 0.1% Tween and 1% BSA (PBSTB), for
30 min at room temperature. The plates were washed again
three times with PBSTB, and alkaline phosphatase-conju-
gated streptavidin (Jackson Immunoresearch, West Grove,
PA) was added (50 ll of 1 : 1000 dilution in PBSTB) and
plates were incubated for 30 min at room temperature.
Plates were washed twice with PBST, incubated with blue
substrate (Vector Labs, # SK-5300; Burlingame, CA) until
spots were clearly visible, and then rinsed with tap water.
When plates were dry, spots were counted using an auto-
mated ELISPOT reader and Immunospot S5 Analyser
(CTL, LLC, Shaker Heights, OH).
Statistical analyses
Groups were compared using non-parametric models;
data were reported with median and 25–75% interquartile
range (IQR). Correlations were performed using the
Spearman non-parametric test and P-values were consid-
ered significant if < 0.05. Results are expressed in medians
and IQR.
Results
Study volunteers and characteristics
The study subjects were distributed into four groups: 22
healthy controls and 23 HIV-1-seropositive patients, most
of whom had CD4+ T-cell counts of < 400 cells/ll, 20
patients with leprosy, classified according to the bacillary
load,17,18 and 17 co-infected patients with both leprosy
and HIV-1 infection, all recruited at the Leprosy Outpa-
tient Clinics at both Para and Sao Paulo sites. The med-
ian age of all participants was 37 years (IQR 35–48 years)
and most were men (81%). No difference in gender dis-
tribution was observed between the groups for the leprosy
and co-infected groups. Most patients had paucibacillary
presentation at the time of diagnosis for both leprosy
groups. Our results demonstrated that healthy controls
had higher CD4+ T-cell counts (median 917 cells/mm3,
IQR 687–1170) when compared with HIV-1-infected
patients (median 391 cells/mm3, IQR 272–536) and co-
infected patients (median 285 cells/mm3, IQR 235–480),
P < 0.001. Leprosy patients had higher numbers of CD4+
T cells (median 733 cells mm3, IQR 699–870) when com-
pared with co-infected patients (P < 0.001). For CD8+ T-
cell counts, healthy controls (median 556 cells/mm3, IQR
376–735) had lower numbers when compared with co-
infected patients (median 806 cells/mm3, IQR 578–1548),
P < 0.05 (Table 1).
Reduced NKT cell frequencies in peripheral blood of
M. leprae-infected subjects
The NKT cells represent a subset of lymphocytes, defined
operationally as bearing both the T-cell receptor and the
NK cell marker CD161 (NK1.1 in mice).19 We defined
NKT cells as those with the CD3+ Va24+ Vb11+ phenotype
Table 1. Demographic and laboratory data
Controls (n = 22) HIV patients (n = 23)
Leprosy patients
(n = 20)
HIV/Leprosy patients
(n = 17)
Demographics
Age (years), median (IQR) 24 (23–36) (n = 17) 34 (33–39.75) (n = 22) 41 (37–49) (n = 17) 34 (30–40) (n = 17)
Gender, % women 64.7% (n = 17) 4.54% (n = 22) 15% (n = 20) 23.52% (n = 17)
Gender, % men 35.3% (n = 17) 95.45% (n = 22) 85% (n = 20) 76.48% (n = 17)
Laboratory findings
HIV-RNA copies/ml,
median
– <400 (n = 22) – <400 (n = 13)
CD3+/CD4+ cells/ll,
median (IQR)
916 (687–1170) (n = 17) 391 (272–536) (n = 22) 733 (699–870) (n = 13) 285 (235–480) (n = 16)
CD3+/CD8+ T cells/ll,
median (IQR)
556 (376–735) (n = 17) 904 (458.5–1098.7) (n = 22) 526 (468–681) (n = 13) 806 (578–1548) (n = 15)
Bacillary load, n (%)
Paucibacillary – – 9 (45%) 13 (77%)
Multibacillary 11 (55%) 4 (23%)
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(Fig. 1a), and further subdivided NKT cell subsets using
CD4, CD161 and HLA-DR. The gating strategy enabled
delineation of CD4+ NKT subsets (Fig. 1b). Because of
the variability of NKT cell frequencies and limitations of
available PBMC, data were included in this study if > 30
events were collected within the NKT gate. Berzins et al.20
reported an NKT cell frequency in adult blood ranging
from 0.006 to 0.78%. Our results demonstrated that the
healthy controls had more NKT cells in the peripheral
blood (median 0.077%, IQR 0.032–0.405) than co-
infected patients (median 0.022%, IQR 0.007–0.051),
P < 0.01. Co-infected patients also had fewer NKT cells
when compared with HIV-1-infected patients (median
0.072%, IQR 0.030–0.160), P < 0.05 (Fig. 2a).
Expression of CD4+ CD161+ HLA-DR– NKT cell
subset in M. leprae infection
The CD4 molecule distinguishes two phenotypic and
functionally distinct subsets of NKT cells. CD4+ NKT
cells were found to produce both T helper type 1 and
type 2 cytokines, whereas CD4) NKT cells mainly pro-
duce T helper type 1 cytokines.21,22 In peripheral blood
from healthy adult volunteers, close to 50% of NKT cells
are CD4) with no, or low, expression of CD8.23 We
observed that leprosy patients have more CD4+ CD161+
HLA-DR– NKT cells (median 21.40%, IQR 3.65–59.95)
compared with HIV-1-infected patients (median 0.375,
IQR 0.00–19.30), P < 0.05 (Fig. 2b), but this was not sta-
tistically different from healthy controls or co-infected
patients.
Activation and maturation NKT cells markers are not
significantly affected in M. leprae/HIV-1 co-infection
We used CD161 and HLA-DR as activation markers to
determine the activation profile of NKT cells. Although
5–10% of human peripheral blood T cells express
CD161,5,24 there were more CD161+ NKT cells in healthy
individuals than in leprosy patients.25 There were no
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Figure 1. Representative flow cytometry plots. (a) From left to the right: single cell gating, lymphocytes, CD3+ T cells; (b) from left to the right:
an example of natural killer T (NKT) cells in each group, double-positive, Va24+ and Vb11+, defining NKT cells; (c) NKT cells CD161+, CD4+
and HLA-DR+ subsets.
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significant differences in CD161 expression on NKT cells
between all four groups. The NKT cells can became acti-
vated during a variety of infections and inflammatory
responses,26 but HLA-DR expression was not significantly
different between study groups.
PBMCs from co-infected patients produce IFN-c in
response to a-GalCer
The NKT cells are activated in response to the glycolipid
antigen a-GalCer and antigen presentation occurs through
CD1d.7 The ELISPOT assay is a sensitive method for
detecting and quantifying antigen-reactive cells in a popu-
lation of lymphocytes with multiple specificities.27 To
determine the frequency of a-GalCer-reactive cells, we
analysed PBMCs in a single-colour ELISPOT assay using
the DX-a-GalCer stimulation method.28 Cells secreting
IFN-c and IL-4 were detected from all four groups.
Results were expressed in spot-forming units (SFU) per
million cells. We demonstrated that, when stimulated
with specific antigen a-GalCer, PBMC from co-infected
patients showed greater secretion of IFN-c (median
10 SFU, IQR 3–14) compared with leprosy mono-infected
patients (median 0 SFU, IQR 0.0–5.5), P < 0.05 (Fig. 3a).
No difference in IL-4 secretion by NKT cells was detected
between the groups (Fig. 3b). However, IFN-c frequencies
in co-infected patients were positively correlated with the
percentage of CD161+ NKT cells (r = 0.81, P = 0.02)
(data not shown).
Discussion
In this study, we demonstrated that patients co-infected
with M. leprae and HIV-1 had lower frequencies of NKT
cells in peripheral blood than healthy subjects and HIV-1-
mono-infected patients.
Although many studies have attributed beneficial anti-
pathogen responses to NKT cells, they have also been
(a)
(b)
P < 0·05
P < 0·05
Healthy
Sp
ot
s 
fo
rm
in
g 
un
its
 IF
N-
g 
 
(S
FC
/m
illio
n P
BM
C)
Sp
ot
s 
fo
rm
in
g 
un
its
 IF
N-
g 
 
(S
FC
/m
illio
n P
BM
C)
HIV Leprosy Dual
Healthy HIV Leprosy Dual
30
20
10
0
30
20
10
0
Figure 2. Expression of total and subsets of natural killer T (NKT)
cells. (a) Representative of NKT cells (log) showing a decreased
expression in dual infection (HIV-1 and leprosy) when compared
with HIV-1 patients (P < 0.05) and healthy donors (P < 0.01). (b)
The percentage of dual expression of CD161+ CD4+ HLA-DR– was
increased in leprosy patients when compared with HIV-1-infected
patients (P < 0.05). Comparisons in all groups were carried out
using the analysis of variance non-parametric test.
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Figure 3. ELISPOT secreting cytokines in total peripheral blood
mononuclear cells (PBMC) with a-galactosylceramide (a-GalCer).
(a) Significant increase in interferon-c (IFN-c) production in dual
infection (HIV plus leprosy) when compared with leprosy patients.
(b) No significant difference in the production of interleukin-4
(IL-4) between the groups. Comparisons in all groups were carried
out using the analysis of variance non-parametric test. SFU,
spot-forming units
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implicated in detrimental immune responses that lead to
immunopathology and disease.8 In HIV-1-infected indi-
viduals, the frequency of NKT cells is markedly reduced
in peripheral blood compared with uninfected controls,2,29,30
and this loss of NKT cells could lead to autoimmunity or to
autoimmune-like conditions. Diminished NKT cell-medi-
ated anti-tumour responses could also contribute to
increased incidence of infection-related tumours such as
Kaposi sarcoma and non-Hodgkin’s lymphoma in AIDS
patients.24 In another human retrovirus infection, lower
numbers of circulating Va24+ Vb11+ NKT cells in indi-
viduals infected with human T lymphotropic virus type 1
(HTLV-1) have been demonstrated.31
Natural killer T cells also participate in host defence
against mycobacterial infection. Some groups have described
lower numbers of NKT cells in peripheral blood of
patients with mycobacterial infections.32,33 There are sig-
nificantly lower percentages of circulating NKT cells in
patients with active pulmonary tuberculosis than in sub-
jects uninfected with Mycobacterium tuberculosis33 and
these cells become activated upon infection.32 Activation
of NKT cells in M. tuberculosis-infected patients could
also mediate anti-mycobacterial responses, which may
translate into a novel treatment modality for humans.7
We hypothesized that in the setting of HIV-1 and M. le-
prae co-infection, NKT cells would be reduced in fre-
quency compared with mono-infection alone, and based
upon the previous studies of M. tuberculosis patients find-
ing activated NKT cells.33 Our results confirm this
hypothesis, indicating that M. leprae infection leads to
significant changes in the NKT cell population, including
the frequency and expression of activation and matura-
tion markers in the peripheral blood. We have previously
demonstrated that co-infected patients had higher activa-
tion markers on T cells.34
CD161 is the homologue of the mouse NK1.1, and is
often used to define the maturation state of NKT cell
populations, with higher expression reflecting a more
mature phenotype.20 NKT cells in HIV-1-infected patients
are compromised and CD161+ CD4+ HLADR NKT cell
subsets decline in these patients compared with mono-
infected leprosy patients. In this study, we observed that
co-infected patients produced greater amounts of IFN-c
when stimulated with a-GalCer. This suggests that NKT
cells in co-infected patients may compensate for the
lower frequency by increasing the production of IFN-c.
We did not detect the same effect in IL-4 production,
but this could be because of differences in the kinetics
of cytokine production in the ELISPOT assay. However,
these cytokines are not always produced concomitantly
at high levels.35 The importance of NKT cells might
depend upon their activation ability early after pathogen
infection, with rapid cytokine production (such as IFN-
c) initiating the immune activation cascade.8 Although
CD161 acts as both an activating and an inhibitory
receptor, depending on cell type,36 we observed that in
co-infected patients the percentage of NKT cells express-
ing CD161 correlated positively with the production of
IFN-c. However, one study observed that in HIV-1 infec-
tion, impairments of T helper type 1 functions were posi-
tively associated with increased frequencies of CD161+
NKT cells.28 In fact, one important effector mechanism by
which NKT cells may contribute to the defence against
infection is such production of cytokines.7
In summary, our results show that both HIV-1 and
M. leprae infections can independently have reduced per-
centages of circulating NKT cells in the peripheral blood,
and that co-infection exacerbates the loss, with a further
decrease in NKT cell numbers. Interestingly, in dual
infection, there appears to be an increase in cytokine pro-
duced from NKT cells suggesting a compensatory mecha-
nism whereby a reduced number of cells produce more
cytokine. Innate immunity in human subjects is strongly
influenced by their spectrum of chronic infections, and in
HIV-1-infected subjects, a concurrent mycobacterial infec-
tion leads to a further reduction in NKT cell numbers,
and skewed innate immunity.
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